HOPE

Study Patients

9297 high-risk patients (aged > 55 yrs; had previous CV event i.e. CAD, stroke or PVD; or diabetes plus one other CV risk factor i.e. hypertension, microalbuminuria, elevated total cholesterol, low HDL-C or current smoking)

Study Groups

Ramipril 10 mg/day vs placebo

Median Study Period

4.5 years

Results

Significantly reduces primary composite outcome of MI, stroke or CV death by 22% vs placebo
Significant reduction in new diagnosis of diabetes by 34% vs palcebo
Significantly reduces individual component vs placebo

Conclusion

Ramipril significantly reduces CV events in high-risk patients with diabetes

N Engl J Med 2000; 342: 145-153

0